ZSQR heads into its June 26 earnings print with one of the tightest borrow markets in the Nasdaq biotech universe — and a stock that has nearly doubled in a month.
The lending picture is the standout here. Availability has recovered slightly to 11% after spending most of the past two weeks below 5% — touching a near-total lockout of just 0.9% on June 11, the tightest reading of the past year. Cost to borrow has tripled since late May, running at 23.4% against roughly 7% a month ago. Short interest has also climbed fast: the estimated short position has more than doubled over the past month, adding nearly 30% in the past week alone. Together, those signals describe a stock where bearish conviction is high but the mechanics of maintaining that position are becoming increasingly punishing.
The price action adds a layer of complexity to that picture. ZSQR has gained 64% over the past month to close at $14.71, a move that will have inflicted significant pain on shorts caught in the rally. Monday's 12% single-day drop, however, snapped that momentum — and with availability still deeply constrained, any further selling into earnings could amplify moves in either direction. Nasdaq biotech peers TSHA and both gained roughly 14% on the week, suggesting the broader small-cap biotech tape remained constructive even as ZSQR pulled back.
The bull and bear debate is unusually binary for a company this size. Bulls point to the dramatic re-rating — 64% in a month implies a meaningful positive catalyst has already been partly priced in, and a strong print could validate the move. Bears counter that with nearly the entire borrowable float already lent out and cost to borrow elevated, the short base is pressing hard against deteriorating fundamentals common to early-stage biotech names. Institutional ownership remains thin, with Vanguard entities accounting for the largest disclosed positions. Analyst and insider data are either absent or too stale to be meaningful here.
The June 26 print is therefore less a test of quarterly numbers and more a verdict on whether the past month's re-rating rests on anything durable — or whether the bears, already paying dearly to hold their positions, get the confirmation they need.
See the live data behind this article on ORTEX.
Open ZSQR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
